Relations lipides–immunité cutanée : exemple des gangliosides

Vyas, 2001, Segregation of gangliosides GM1 and GD3 on cell membranes, isolated membrane rafts and defined supported lipid monolayers, Biol Chem, 382, 241, 10.1515/BC.2001.031 Michel, 1997, Conversion of dihydroceramide to ceramide occurs at the cytosolic face of the endoplasmic reticulum, Febs Lett, 416, 153, 10.1016/S0014-5793(97)01187-3 Allende, 2000, Evidence supportinga late Golgi location for lactosylceramide to ganglioside GM3 conversion, Glycobiology, 10, 1025, 10.1093/glycob/10.10.1025 Werth, 2001, Degradation of membrane-bound ganglioside GM2 by beta -hexosaminidase A, Stimulation by GM2 activator protein and lysosomal lipids, J Biol Chem, 276, 12 685, 10.1074/jbc.M007970200 Spiegel, 1988, Insertion of ganglioside GM1 into rat glioma C6 cells renders them susceptible to growth inhibition by the B subunit of cholera toxin, Biochim Biophys Acta, 969, 249, 10.1016/0167-4889(88)90059-6 Fantini, 2000, Role of glycosphingolipid microdomains in CD4-dependent HIV-1 fusion, Glycoconj J, 17, 199, 10.1023/A:1026537122903 Portoukalian, 1978, Alteration of gangliosides in plasma and red cells of humans bearing melanoma tumors, Biochem Biophys Res Commun, 85, 916, 10.1016/0006-291X(78)90630-7 Rebbaa, 1995, The distribution of exogenously added gangliosides in serum proteins depends on the relative affinities of lipoproteins and albumin, J Lipid Res, 36, 564, 10.1016/S0022-2275(20)39890-4 Portoukalian, 1989, Immunoregulatory activity of gangliosides shed by melanoma tumors Miller, 1975, Modulation of the immune response by antigen-reactive lymphocytes after cultivation with gangliosides, J Immunol, 115, 839, 10.4049/jimmunol.115.3.839 Portoukalian, 1989, Tumor size-dependent elevations of serum gangliosides in patients with head and neck carcinomas, Biochem Int, 18, 759 Kanda, 1999, Ganglioside GD1b suppresses immunoglobulin production by human peripheral blood mononuclear cells, Exp Hematol, 27, 1487, 10.1016/S0301-472X(99)00093-4 Ladisch, 1992, Immunosuppression by human gangliosides: I. Relationship of carbohydrate structure to the inhibition of T cell responses, Biochim Biophys Acta, 1125, 180, 10.1016/0005-2760(92)90043-U Grayson, 1992, Immunosuppression by human gangliosides, II. Carbohydrate structure and inhibition of human NK activity, Cell Immunol, 139, 18, 10.1016/0008-8749(92)90096-8 Shurin, 2001, Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function, Cancer Res, 61, 363 McKallip, 1999, Tumor gangliosides inhibit the tumor-specific immune response, J Immunol, 163, 3718, 10.4049/jimmunol.163.7.3718 Ladisch, 1994, Ceramide structure predicts tumor ganglioside immunosuppressive activity, Proc Natl Acad Sci USA, 91, 1974, 10.1073/pnas.91.5.1974 Chu, 1993, Gangliosides inhibit T-lymphocyte proliferation by preventing the interaction of interleukin-2 with its cell surface receptors, Immunology, 79, 10 Ravindranath, 2001, Interleukin-2 binds to ganglioside GD1b, Biochem. Biophys, Res Commun, 283, 369, 10.1006/bbrc.2001.4797 Molotkovskaya, 2000, Gangliosides induce cell apoptosis in the cytotoxic line CTLL-2, but not in the promyelocytic leukemia cell line HL-60, Membr Cell Biol, 13, 811 Chu, 1995, Gangliosides interact with interleukin-4 and inhibit interleukin-4-stimulated helper T-cell proliferation, Immunology, 84, 396 Morioka, 1991, Gangliosides inhibit the proliferation of human T cells stimulated with interleukin-4 or interleukin-2, J Dermatol, 18, 447, 10.1111/j.1346-8138.1991.tb03114.x Hillman, 1995, Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma model, Cell Immunol, 160, 257, 10.1016/0008-8749(95)80036-I